Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics

Magenta Therapeutics, Inc. (MGTA)

Today's Latest Price: $9.19 USD

0.23 (-2.44%)

Updated May 28 6:55pm

Add MGTA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MGTA Daily Price Range
MGTA 52-Week Price Range

MGTA Stock Price Chart More Charts

MGTA Price/Volume Stats

Current price $9.19 52-week high $16.87
Prev. close $9.42 52-week low $5.76
Day low $9.09 Volume 156,100
Day high $9.87 Avg. volume 154,584
50-day MA $8.15 Dividend yield N/A
200-day MA $10.87 Market Cap 362.86M

Magenta Therapeutics, Inc. (MGTA) Company Bio

Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.

MGTA Latest News Stream

Event/TimeNews Detail
Loading, please wait...

MGTA Latest Social Stream

Loading social stream, please wait...

View Full MGTA Social Stream

Latest MGTA News From Around the Web

Below are the latest news stories about Magenta Therapeutics Inc that investors may wish to consider to help them evaluate MGTA as an investment opportunity.

Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of blood and immune reset to more patients, presented preclinical data on its stem cell mobilization therapy clinical candidate, MGTA-145, this week at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT).

Yahoo | May 14, 2020

ArcherDX Appoints Jason Ryan to Board of Directors

BOULDER, Colo., May 7, 2020 /PRNewswire/ -- ArcherDX, Inc. today announced the appointment of Jason Ryan, Chief Operating and Financial Officer at Magenta Therapeutics and former Chief Financial Officer at Foundation Medicine, to the company's Board of Directors and as the Chair of the…

PR Newswire | May 7, 2020

AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended March 31, 2020 and provided a business update. “Our strong progress has continued, as evidenced by recently announced collaborations with Saladax Biomedical, Inc. and Magenta Therapeutics, which highlight our commitment to leading innovation in the lentiviral gene th

Business Wire | May 7, 2020

AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of AVROBIO’s investigational lentiviral gene therapies. The collaboration will combine AVROBIO’s leadership in lentiviral gene therapies with Magenta’s expertise in ADC-based cond

Business Wire | May 6, 2020

Magenta Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Magenta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research | October 9, 2019

Read More 'MGTA' Stories Here

MGTA Price Returns

1-mo 2.22%
3-mo -21.85%
6-mo -30.59%
1-year -40.09%
3-year N/A
5-year N/A
YTD -39.38%
2019 165.96%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7167 seconds.